Predictors of NLE risk and specific manifestations (n = 324).
| Covariate | NLE | Cardiac | Cutaneous OR (95% CI), P | Hematologic | Hepatic | Neurologic |
|---|---|---|---|---|---|---|
| Child ethnicity (ref: European) | ||||||
| Non-European | 1.18 (0.71–1.94), 0.51 | 0.53 (0.19–1.43), 0.21 | 1.48 (0.67–3.25), 0.32 | 1.40 (0.76–2.60), 0.27 | 1.04 (0.59–1.84), 0.86 | 0.36 (0.10–1.31), 0.12 |
| Mixed European–non-European | 1.13 (0.59–2.16), 0.70 | 0.91 (0.28–2.89), 0.88 | 0.87 (0.28–2.67), 0.81 | 0.85 (0.36–1.98), 0.70 | 1.39 (0.69–2.81), 0.34 | 0.54 (0.10–2.79), 0.47 |
| Male sex (ref: female) | 0.71 (0.46–1.11), 0.14 | 0.52 (0.21–1.29), 0.16 | 0.98 (0.49–1.95), 0.95 | 0.63 (0.36–1.09), 0.10 | 0.54 (0.33–0.90), 0.01 | 2.35 (0.70–7.88), 0.16 |
| Antimalarials in pregnancy | 0.78 (0.46–1.30), 0.34 | 0.80 (0.24–2.67), 0.72 | 0.68 (0.29–1.55), 0.36 | 0.84 (0.46–1.54), 0.57 | 0.58 (0.32–1.05), 0.07 | 1.46 (0.40–5.38), 0.56 |
| Maternal rheumatic disease | 0.87 (0.50–1.51), 0.63 | 0.30 (0.11–0.83), 0.02 | 1.00 (0.44–2.27), 0.99 | 2.21 (1.07–4.55), 0.03 | 0.99 (0.55–1.80), 0.99 | 1.10 (0.24–4.96), 0.90 |
Multivariable models adjusted for child’s ethnicity, sex, antimalarial use during pregnancy, and maternal rheumatic disease status. NLE: neonatal lupus erythematosus.